An integrated approach for detection and characterization of the trace impurities in levofloxacin using liquid chromatography-tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 28, Issue 10, 2014, Pages 1164-1174

  Zheng, Ya Jie ^a   He, Jiu Ming ^a   Zhang, Rui Ping ^a   Wang, Yu Cheng ^b   Wang, Ju Xian ^b   Wang, Hui Qing ^a   Wu, Yan ^a   He, Wen Yi ^a   Abliz, Zeper ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; INTEGRATED CONTROL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; QUALITY CONTROL; SCREENING;

IMPURITIES IN; IMPURITY ANALYSIS; IMPURITY SCREENING; INTEGRATED APPROACH; LEVOFLOXACIN; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; SCREENING METHODS; TRACE IMPURITIES; TRACE LEVEL;

IMPURITIES;

LEVOFLOXACIN;

CHEMISTRY; DRUG CONTAMINATION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; LEVOFLOXACIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84898026555     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6886     Document Type: Article

References (34)

1. G. Xue, A. D. Bendick, R. Chen, S. S. Sekulic,. Automated peak tracking for comprehensive impurity profiling in orthogonal liquid chromatographic separation using mass spectrometric detection. J. Chromatogr. A 2004, 1050, 159.
2. C. Pan, F. Liu, M. Motto,. Identification of pharmaceutical impurities in formulated dosage forms. J. Pharm. Sci. 2011, 100, 1228.
3. S. Singh, T. Handa, M. Narayanam, A. Sahu, M. Junwal, R. P. Shah,. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. J. Pharm. Biomed. Anal. 2012, 69, 148.
4. V. Neu, C. Bielow, I. Gostomski, R. Wintringer, R. Braun, K. Reinert, P. Schneider, H. Stuppner, C. G. Huber,. Rapid and comprehensive impurity profiling of synthetic thyroxine by ultrahigh-performance liquid chromatography-high- resolution mass spectrometry. Anal. Chem. 2013, 85, 3309.
5. W. Li, C.Q. Hu,. Spectral correlation of high-performance liquid chromatography-diode array detection data from two independent chromatographic runs peak tracking in pharmaceutical impurity profiling. J. Chromatogr. A 2008, 1190, 141.
6. M. Dumarey, R. Sneyers, W. Janssens, I. Somers, Y. Vander Heyden,. Drug impurity profiling: Method optimization on dissimilar chromatographic systems: Part I: pH optimization of the aqueous phase. Anal. Chim. Acta 2009, 656, 85.
7. C. S. Wu, Y. F. Tong, P. Y. Wang, D. M. Wang, S. Wu, J. L. Zhang,. Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun. Mass Spectrom. 2013, 27, 971.
8. T. Bristow, M. Harrison, M. Sims,. The application of gas chromatography/atmospheric pressure chemical ionisation time-of-flight mass spectrometry to impurity identification in Pharmaceutical Development. Rapid Commun. Mass Spectrom. 2010, 24, 1673.
9. Z. Fu, L. Wang, Y. Wang,. Capillary electrophoresis- electrochemiluminescent detection of N,N-dimethylethanolamine and its application in impurity profiling and stability investigation of meclophenoxate. Anal. Chim. Acta 2009, 638, 220.
10. P. Hommerson, A. M. Khan, T. Bristow, M. W. Harrison, G. J. de Jong, G. W. Somsen,. Drug impurity profiling by capillary electrophoresis/mass spectrometry using various ionization techniques. Rapid Commun. Mass Spectrom. 2009, 23, 2878.
11. S. Provera, L. Martini, G. Guercio, L. Turco, L. Costa, C. Marchioro,. Application of LC-NMR and HR-NMR to the characterization of biphenyl impurities in the synthetic route development for vestipitant, a novel NK1 antagonist. J. Pharm. Biomed. Anal. 2010, 53, 389.
12. M. J. Fredriksson, P. Petersson, B.O. Axelsson, D. Bylund,. An automatic peak finding method for LC-MS data using Gaussian second derivative filtering. J. Sep. Sci. 2009, 32, 3906.
13. X. Wang, H. Zhou, J. Zheng, C. Huang, W. Liu, L. Yu, S. Zeng,. Identification and characterization of four process-related impurities in retigabine. J. Pharm. Biomed. Anal. 2012, 71, 148.
14. M. Zhu, H. Zhang, W. G. Humphreys,. Drug metabolite profiling and identification by high-resolution mass spectrometry. J. Biol. Chem. 2011, 286, 25419.
15. H. Zhang, Y. Yang,. An algorithm for thorough background subtraction from high-resolution LC/MS data: application for detection of glutathione-trapped reactive metabolites. J. Mass Spectrom. 2008, 43, 1181.
16. H. Zhang, M. Grubb, W. Wu, J. Josephs, W. G. Humphreys,. Algorithm for thorough background subtraction of high-resolution LC/MS data: application to obtain clean product ion spectra from nonselective collision-induced dissociation experiments. Anal. Chem. 2009, 81, 2695.
17. C. S. Lewin, S. G. Amyes,. The bactericidal activity of DR-3355, an optically active isomer of ofloxacin. J. Med. Microbiol. 1989, 30, 227.
18. T. Fujimoto, S. Mitsuhashi,. In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy 1990, 36, 268.
19. J. M. Domagala,. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 1994, 33, 685.
20. Y. Kashida, M. Kato,. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob. Agents Chemother. 1997, 41, 2389.
21. Y. Yoshida, E. Sato, R. Moroi,. Photodegradation products of levofloxacin in aqueous solution. Arzneimittelforschung 1993, 43, 601.
22. M. Lalitha Devi, K. B. Chandrasekhar,. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant. J. Pharm. Biomed. Anal. 2009, 50, 710.
23. The United States Pharmacopeia Convention. The 35th Revision of the United States Pharmacopeia (USP 36). Available: http://www.usp.org/sites/ default/files/usp-pdf /EN/USPNF/revisions/levofloxacin.pdf.
24. The Pharmacopoeia of the People's Republic of China, Part II. China Medical Science and Technology Press, Beijing, 2010, p. 106.
25. The Japanese Pharmacopoeia (English Electric Version), Sixteenth Edition. Issued on 24 March 2011, last updated: February 27, 2012.
26. J. N. Sateesh, G. V. Subbareddy, K. N. Jayaveera, S. D. Hayalamurthi,. A validated stability-indicating isocratic LC method for levofloxacin in the presence of degradation products and its process-related impurities. Acta Chromatogr. 2012, 24, 23.
27. W. J. Wang, T. Li, J. Li, Q. Liu, Y. C. Xie,. HPLC-MS identification of degradation products of levofloxacin. Yao Xue Xue Bao 2012, 47, 498.
28. S. Ma, S. K. Chowdhury,. Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS. Bioanalysis 2013, 5, 1285.
29. F. Gosetti, U. Chiuminatto, E. Mazzucco, G. Calabrese, M. C. Gennaro, E. Marengo,. Identification of photodegradation products of Allura Red AC (E129) in a beverage by ultra high performance liquid chromatography-quadrupole-time-of- flight mass spectrometry. Anal. Chim. Acta 2012, 746, 84.
30. ICH Guidelines Q3A(R2). Impurities in new drug substances. International Conference on Harmonisation, IFPMA, Geneva, Switerland, October 25, 2006.
31. H. Zhang, D. Zhang, K. Ray, M. Zhu,. Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J. Mass Spectrom. 2009, 44, 999.
32. H. Zhang, L. Ma, K. He, M. Zhu,. An algorithm for thorough background subtraction from high-resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. J. Mass Spectrom. 2008, 43, 1191.
33. A. Awasthi, M. Razzak, R. Al-Kassas, D. R. Greenwood, J. Harvey, S. Garg,. Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H/D exchange, and NMR. J. Pharm. Biomed. Anal. 2012, 63, 62.
34. X.R. Liang, Z.L. Guo, C.M. Yu,. Fragmentation pathways of 2-substituted pyrrole derivatives using electrospray ionization ion trap and electrospray ionization quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2013, 27, 2272.